CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Regeneron reported first-in-human Phase 1/2 results for CIDEB(siRNA) showing a single subcutaneous dose produced 58-80% dose-dependent liver fat reductions sustained through week 36 in MASLD patients. Sixty-two percent of treated patients normalized liver fat at week 36 and 93% achieved reductions of at least 30%, versus a 2.9% mean decrease on placebo; no nausea, vomiting, or discontinuations were seen in treated groups. The data were published in NEJM and presented at AASLD, positioning CIDEB(siRNA) — developed with Alnylam, which receives milestones and royalties — against approved MASH therapies that achieved only 47-57% fat reduction at about one year.
Key figures
- Drug Name
- CIDEB(siRNA) (ALN-CIDEB)
- Phase Of Trial
- Phase 1/2
- Mash us patients
- ~13 million adults
- Liver fat reduction week6
- 49-72%
- Liver fat reduction week36
- 58-80% dose-dependent
- Placebo liver fat change week36
- mean 2.9% decrease
- Patients liver fat reduction ge30
- 93%
- Patients normalized liver fat week36
- 62%
- Historical approved therapy fat reduction
- 47-57% at ~1 year
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.